While Immunovant Inc has underperformed by -1.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IMVT fell by -36.42%, with highs and lows ranging from $34.47 to $12.72, whereas the simple moving average fell by -29.36% in the last 200 days.
On March 03, 2025, Jefferies started tracking Immunovant Inc (NASDAQ: IMVT) recommending Hold. A report published by Wolfe Research on January 03, 2025, Downgraded its rating to ‘Peer Perform’ for IMVT. Raymond James also rated IMVT shares as ‘Outperform’, setting a target price of $36 on the company’s shares in an initiating report dated October 10, 2024. Oppenheimer Reiterated the rating as Outperform on October 09, 2024, but set its price target from $47 to $53. Oppenheimer initiated its ‘Outperform’ rating for IMVT, as published in its report on March 28, 2024. Goldman’s report from March 13, 2024 suggests a price prediction of $50 for IMVT shares, giving the stock a ‘Buy’ rating. JP Morgan also rated the stock as ‘Overweight’.
Analysis of Immunovant Inc (IMVT)
To gain a thorough understanding of Immunovant Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -62.46% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.16, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and IMVT is recording an average volume of 1.59M. On a monthly basis, the volatility of the stock is set at 2.79%, whereas on a weekly basis, it is put at 2.47%, with a gain of 2.87% over the past seven days. Furthermore, long-term investors anticipate a median target price of $43.38, showing growth from the present price of $15.75, which can serve as yet another indication of whether IMVT is worth investing in or should be passed over.
How Do You Analyze Immunovant Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 59.89%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 55.66% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IMVT shares are owned by institutional investors to the tune of 55.66% at present.
